Literature DB >> 20441247

Mesalazine-induced multi-organ hypersensitivity.

Bruno Sposato1, Maria Pia Allegri, Maria Piera Riccardi, Silvia Chigiotti, Cesira Nencioni, Barbara Ricciardi, Tiziana Carli, Alberto Cresti, Maria Grazia Perari, Maria Giovanna Migliorini, Mario Toti.   

Abstract

Mesalazine therapy for ulcerative colitis has been reported to be effective and safe. Rare cases of mesalazine-induced renal, pancreatic, myo-pericardial, pleuro-pulmonary and haematological toxicity have been described separately. We report a case characterized by the simultaneous presence of fever, pericarditis, peripheral eosinophilia, eosinophilic pneumonia, anaemia and haematuria (together with proteinuria and leukocyturia) due to mesalazine treatment in a patient with ulcerative colitis. No clinical response had been obtained with corticosteroids and various antibacterial agents. When mesalazine treatment was suspended, all symptoms rapidly and totally disappeared, confirming the direct responsibility of this drug in causing these adverse events. We conclude that mesalazine can induce multi-organ hypersensitivity, which must always be considered as a possible adverse effect during treatment with this drug. To resolve this adverse event it is essential to discontinue mesalazine treatment.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20441247     DOI: 10.1007/bf03256911

Source DB:  PubMed          Journal:  Clin Drug Investig        ISSN: 1173-2563            Impact factor:   2.859


  12 in total

1.  Mesalazine-induced aplastic anemia.

Authors:  Ari Wiesen; Jonathan Wiesen; Sewanti Limaye; Neeraj Kaushik
Journal:  Am J Gastroenterol       Date:  2009-03-03       Impact factor: 10.864

2.  Mesalamine-associated hypersensitivity myocarditis in ulcerative colitis.

Authors:  Sundae Stelts; Marian H Taylor; Jean Nappi; Adrian B Van Bakel
Journal:  Ann Pharmacother       Date:  2008-04-22       Impact factor: 3.154

Review 3.  Acute pancreatitis secondary to 5-aminosalicylic acid therapy in a patient with ulcerative colitis.

Authors:  E Adachi; K Okazaki; Y Matsushima; H Seno; K Uchida; H Nakase; C Kawanami; T Nakamura; T Chiba
Journal:  Int J Pancreatol       Date:  1999-06

Review 4.  5-Aminosalicylates and renal function in inflammatory bowel disease: a systematic review.

Authors:  Javier P Gisbert; Yago González-Lama; José Maté
Journal:  Inflamm Bowel Dis       Date:  2007-05       Impact factor: 5.325

5.  A method for estimating the probability of adverse drug reactions.

Authors:  C A Naranjo; U Busto; E M Sellers; P Sandor; I Ruiz; E A Roberts; E Janecek; C Domecq; D J Greenblatt
Journal:  Clin Pharmacol Ther       Date:  1981-08       Impact factor: 6.875

6.  Acute pericarditis associated with 5-aminosalicylic acid (5-ASA) treatment for severe active ulcerative colitis.

Authors:  N Ishikawa; T Imamura; K Nakajima; J Yamaga; H Yuchi; M Ootsuka; H Inatsu; T Aoki; T Eto
Journal:  Intern Med       Date:  2001-09       Impact factor: 1.271

7.  Bilateral pulmonary infiltrates in a patient with ulcerative colitis receiving mesalazine.

Authors:  Prabath W B Nanayakkara; Evelien de Jong; Piet E Postmus
Journal:  Eur J Intern Med       Date:  2004-11       Impact factor: 4.487

8.  Pancytopenia associated with 5-aminosalicylic acid use in a patient with Crohn's disease.

Authors:  H Kotanagi; M Ito; K Koyama; M Chiba
Journal:  J Gastroenterol       Date:  1998-08       Impact factor: 7.527

Review 9.  Mesalazine-induced eosinophilic pneumonia.

Authors:  K Tanigawa; K Sugiyama; H Matsuyama; H Nakao; K Kohno; Y Komuro; Y Iwanaga; K Eguchi; M Kitaichi; H Takagi
Journal:  Respiration       Date:  1999       Impact factor: 3.580

Review 10.  Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis.

Authors:  E V Loftus; S V Kane; D Bjorkman
Journal:  Aliment Pharmacol Ther       Date:  2004-01-15       Impact factor: 8.171

View more
  5 in total

1.  A large chronic pericardial effusion in an ultramarathon runner with anti-CCP positive rheumatoid arthritis.

Authors:  Thomas J McClelland; Rose Penfold; Stefan Kluzek; Navraj S Nagra
Journal:  BMJ Case Rep       Date:  2017-06-13

2.  Gastroenterology case report of mesalazine-induced cardiopulmonary hypersensitivity.

Authors:  José Ferrusquía; Isabel Pérez-Martínez; Ricardo Gómez de la Torre; María Luisa Fernández-Almira; Ruth de Francisco; Luis Rodrigo; Sabino Riestra
Journal:  World J Gastroenterol       Date:  2015-04-07       Impact factor: 5.742

Review 3.  5-Aminosalicylic Acid-Associated Myocarditis and Pericarditis: A Narrative Review.

Authors:  Glen Brown
Journal:  Can J Hosp Pharm       Date:  2016-12-23

4.  Ulcerative colitis flair induced by mesalamine suppositories hypersensitivity.

Authors:  Hao Ding; Xiao-Chang Liu; Qiao Mei; Jian-Ming Xu; Xiang-Yang Hu; Jing Hu
Journal:  World J Gastroenterol       Date:  2014-04-07       Impact factor: 5.742

Review 5.  Cardiovascular Manifestations in Inflammatory Bowel Disease: A Systematic Review of the Pathogenesis and Management of Pericarditis.

Authors:  Ravi S Patel; Sai Rohit Reddy; Adiona Llukmani; Ayat Hashim; Dana R Haddad; Dutt S Patel; Farrukh Ahmad; Domonick K Gordon
Journal:  Cureus       Date:  2021-03-20
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.